engleski

Latanoprost monotherapy is effective antiglaucoma treatment for patients resistant to beta-blockers

Glaucoma is a major global cause of blindness. Its prevalence varies between countries and increases with age. Latanoprost (PhXA41) is a prostaglandin analogue which has a novel mechanism of action on intraocular pressure. We analysed ocular hypotensive efficacy of latanoprost (Xalatan), in a clinical trial conducted on 157 patients. Xalatan is a topical solution containing latanoprost 0.005% as the active ingredient. The results of the study indicate that latanoprost (Xalatan) may be an useful therapeutic agent in glaucoma patients resistant to beta-blockers. Chemistry, biochemistry and modes of action of latanoprost will be discussed.

glaucona; latanoprost; beta-blockers; patients; monotherapy

nije evidentirano